Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
IntroductionParkinson's Disease (PD) represents the second most prevalent neurodegenerative disorder globally, with traditional assessment methods suffering from limitations including substantial inter-rater variability and inability to capture multifactorial complexity underlying disease progression.MethodsBased on data from 500 Parkinson's disease patients, we integrated 7 standardized clinical phenotypes (excluding UPDRS to prevent data leakage) and 8 environmental exposure factors, compared 10 machine learning algorithms using 5-fold cross-validation, and applied SHAP interpretability analysis for transparent feature importance assessment.ResultsXGBoost with SMOTE sampling achieved clinically meaningful discriminative performance (AUC = 0.781, precision = 0.548, recall = 0.750) appropriate for screening applications. SHAP analysis revealed non-motor symptoms as the primary predictor (SHAP value = 2.76), followed by serum dopamine concentration (2.39) and age (2.16), while environmental factors demonstrated modest but statistically significant contributions.DiscussionThis proof-of-concept study developed an interpretable framework with methodological safeguards against data leakage, demonstrating promising screening potential with realistic performance expectations. However, the cross-sectional, single-center design limits generalizability, requiring external validation and longitudinal studies before clinical deployment.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.